Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-12-2011 | Original Article

Quantification of receptor-ligand binding with [¹⁸F]fluciclatide in metastatic breast cancer patients

Authors: Giampaolo Tomasi, Laura Kenny, Francesco Mauri, Federico Turkheimer, Eric O. Aboagye

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2011

Abstract

Purpose

The purpose of the study was to estimate the receptor-ligand binding of an arginine-glycine-aspartic acid (RGD) peptide in somatic tumours. To this aim, we employed dynamic positron emission tomography (PET) data obtained from breast cancer patients with metastases, studied with the α_vβ_3/5 integrin receptor radioligand [¹⁸F]fluciclatide.

Methods

First, compartmental modelling and spectral analysis with arterial input function were performed at the region of interest (ROI) level in healthy lung and liver, and in lung and liver metastases; compartmental modelling was also carried out at the pixel level. The selection of the most appropriate indexes for tumour/healthy tissue differentiation and for estimation of specific binding was then assessed.

Results

The two-tissue reversible model emerged as the best according to the Akaike Information Criterion. Spectral analysis confirmed the reversibility of tracer kinetics. Values of kinetic parameters, estimated as mean from parametric maps, correlated well with those computed from ROI analysis. The volume of distribution V_T was on average higher in lung metastases than in the healthy lung, but lower in liver metastases than in the healthy liver. In agreement with the expected higher α_vβ_3/5 expression in pathology, k₃ and k₃/k₄ were both remarkably higher in metastases, which makes them more suitable than V_T for tumour/healthy tissue differentiation. The ratio k₃/k₄, in particular, appeared a reasonable measure of specific binding.

Conclusion

Besides establishing the best quantitative approaches for the analysis of [¹⁸F]fluciclatide data, this study indicated that the k₃/k₄ ratio is a reasonable measure of specific binding, suggesting that this index can be used to estimate α_vβ_3/5 receptor expression in oncology, although further studies are necessary to validate this hypothesis.

Available only for authorised users

Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008;49(3):367–74. doi:10.2967/jnumed.107.047506.PubMedCrossRef

Sekar TV, Dhanabalan A, Paulmurugan R. Imaging cellular receptors in breast cancers: an overview. Curr Pharm Biotechnol 2011;12:508–27. doi:BSP/CPB/E-Pub/00082-12-7.

Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 2011;71(1):143–53. doi:10.1158/0008-5472.CAN-10-1088.

Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A et al. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010;54(1):3–15. doi:R39102241.

Pantaleo MA, Mishani E, Nanni C, Landuzzi L, Boschi S, Nicoletti G et al. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol Imaging Biol 2010;12(6):616–25. doi:10.1007/s11307-010-0315-z.

Brooks PC. Role of integrins in angiogenesis. Eur J Cancer 1996;32A(14):2423–9.PubMedCrossRef

Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999;18(3):345–57.PubMedCrossRef

Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4(11):2625–34.PubMed

Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312(5777):1171–5. doi:10.1126/science.1125950.PubMedCrossRef

10.

Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2(3):e70. doi:10.1371/journal.pmed.0020070.PubMedCrossRef

11.

McParland BJ, Miller MP, Spinks TJ, Kenny LM, Osman S, Khela MK, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med 2008;49(10):1664–7. doi:10.2967/jnumed.108.052126.PubMedCrossRef

12.

Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008;49(6):879–86. doi:10.2967/jnumed.107.049452.PubMedCrossRef

13.

Glaser M, Morrison M, Solbakken M, Arukwe J, Karlsen H, Wiggen U, et al. Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups. Bioconjug Chem 2008;19(4):951–7. doi:10.1021/bc700472w.PubMedCrossRef

14.

Tomasi G, Bertoldo A, Bishu S, Unterman A, Smith CB, Schmidt KC. Voxel-based estimation of kinetic model parameters of the L-[1-(11)C]leucine PET method for determination of regional rates of cerebral protein synthesis: validation and comparison with region-of-interest-based methods. J Cereb Blood Flow Metab 2009;29(7):1317–31. doi:10.1038/jcbfm.2009.52.PubMedCrossRef

15.

Bertoldo A, Vicini P, Sambuceti G, Lammertsma AA, Parodi O, Cobelli C. Evaluation of compartmental and spectral analysis models of [18F]FDG kinetics for heart and brain studies with PET. IEEE Trans Biomed Eng 1998;45(12):1429–48. doi:10.1109/10.730437.PubMedCrossRef

16.

Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19(6):716–23.CrossRef

17.

Turkheimer FE, Hinz R, Cunningham VJ. On the undecidability among kinetic models: from model selection to model averaging. J Cereb Blood Flow Metab 2003;23(4):490–8.PubMedCrossRef

18.

Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993;13(1):15–23.PubMedCrossRef

19.

Turkheimer F, Moresco RM, Lucignani G, Sokoloff L, Fazio F, Schmidt K. The use of spectral analysis to determine regional cerebral glucose utilization with positron emission tomography and [18F]fluorodeoxyglucose: theory, implementation, and optimization procedures. J Cereb Blood Flow Metab 1994;14(3):406–22.PubMedCrossRef

20.

Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10(5):740–7.PubMedCrossRef

21.

Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 2002;22(10):1271–81. doi:10.1097/00004647-200210000-00015.PubMedCrossRef

22.

DuBois DDE. A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med 1916;17:863–71.

23.

Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13(22 Pt 1):6610–6. doi:10.1158/1078-0432.CCR-07-0528.PubMedCrossRef

24.

Gray KR, Contractor KB, Kenny LM, Al-Nahhas A, Shousha S, Stebbing J, et al. Kinetic filtering of [(18)F]fluorothymidine in positron emission tomography studies. Phys Med Biol 2010;55(3):695–709. doi:10.1088/0031-9155/55/3/010.PubMedCrossRef

25.

Munk OL, Bass L, Roelsgaard K, Bender D, Hansen SB, Keiding S. Liver kinetics of glucose analogs measured in pigs by PET: importance of dual-input blood sampling. J Nucl Med 2001;42(5):795–801.PubMed

26.

Soo CS, Chuang VP, Wallace S, Charnsangavej C, Carrasco H. Treatment of hepatic neoplasm through extrahepatic collaterals. Radiology 1983;147(1):45–9.PubMed

27.

Taylor I, Bennett R, Sherriff S. The blood supply of colorectal liver metastases. Br J Cancer 1978;38(6):749–56.PubMedCrossRef

28.

Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001;49(2):380–9. discussion 390.PubMed

29.

Haubrich WS. Kupffer of Kupffer cells. Gastroenterology 2004;127(1):16.PubMedCrossRef

30.

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006;12(13):3942–9. doi:10.1158/1078-0432.CCR-06-0266.PubMedCrossRef

31.

Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled alphaVbeta3-integrin and alphaV beta5-integrin imaging agent. J Nucl Med 2011;52(3):424–30. doi:10.2967/jnumed.110.077479.

32.

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27(9):1533–9. doi:10.1038/sj.jcbfm.9600493.PubMedCrossRef

33.

Huang SC, Yu DC, Barrio JR, Grafton S, Melega WP, Hoffman JM, et al. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies. J Cereb Blood Flow Metab 1991;11(6):898–913. doi:10.1038/jcbfm.1991.155.PubMedCrossRef

Title: Quantification of receptor-ligand binding with [18F]fluciclatide in metastatic breast cancer patients
Authors: Giampaolo Tomasi
Laura Kenny
Francesco Mauri
Federico Turkheimer
Eric O. Aboagye
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1907-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quantification of receptor-ligand binding with [¹⁸F]fluciclatide in metastatic breast cancer patients

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2011

18F-Fluorocholine integrated PET/MRI for the initial staging of prostate cancer

Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology

Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy

Certificate of Fellowship of the European Board of Nuclear Medicine 2012 Information

Radioembolisation of hepatocellular carcinoma patients using 90Y-labelled microspheres: towards a diffusion of the technique?

Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine – a review